Literature DB >> 2539523

Association of p60fyn with middle tumor antigen in murine polyomavirus-transformed rat cells.

I D Horak1, T Kawakami, F Gregory, K C Robbins, J B Bolen.   

Abstract

Rabbit antisera raised against human FYN-specific peptides were used to evaluate the expression of the fyn gene product in normal and murine polyomavirus middle tumor antigen (MTAg)-transformed rat cells. The antisera were capable of detecting p60fyn in both normal and MTAg-transformed cells. Two different antisera directed against unique p60fyn sequences were found to detect p60fyn-MTAg complexes in cell lysates from the MTAg-transformed cells. The MTAg molecules immunoprecipitated by FYN antisera were phosphorylated on tyrosine during immune-complex kinase reactions at sites similar to those found on MTAg in complexes with pp60c-src. Whereas the abundance of p60fyn was estimated to be less in the MTAg-transformed cells than in their normal counterparts, the specific activities of p60fyn molecules in the normal and transformed cells were similar.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539523      PMCID: PMC250654     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Structural and functional modification of pp60c-src associated with polyoma middle tumor antigen from infected or transformed cells.

Authors:  C A Cartwright; M A Hutchinson; W Eckhart
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

2.  Restriction of the in vitro and in vivo tyrosine protein kinase activities of pp60c-src relative to pp60v-src.

Authors:  P M Coussens; J A Cooper; T Hunter; D Shalloway
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

3.  Middle tumor antigen of polyomavirus transformation-defective mutant NG59 is associated with pp60c-src.

Authors:  J B Bolen; M A Israel
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

4.  Enhancement of cellular src gene product associated tyrosyl kinase activity following polyoma virus infection and transformation.

Authors:  J B Bolen; C J Thiele; M A Israel; W Yonemoto; L A Lipsich; J S Brugge
Journal:  Cell       Date:  1984-10       Impact factor: 41.582

5.  Isolation of monoclonal antibodies that recognize the transforming proteins of avian sarcoma viruses.

Authors:  L A Lipsich; A J Lewis; J S Brugge
Journal:  J Virol       Date:  1983-11       Impact factor: 5.103

6.  Transformation of rat cells by an altered polyoma virus genome expressing only the middle-T protein.

Authors:  R Treisman; U Novak; J Favaloro; R Kamen
Journal:  Nature       Date:  1981-08-13       Impact factor: 49.962

7.  Mutations around the NG59 lesion indicate an active association of polyoma virus middle-T antigen with pp60c-src is required for cell transformation.

Authors:  S H Cheng; W Markland; A F Markham; A E Smith
Journal:  EMBO J       Date:  1986-02       Impact factor: 11.598

8.  Peptide antibodies to the human c-fyn gene product demonstrate pp59c-fyn is capable of complex formation with the middle-T antigen of polyomavirus.

Authors:  S H Cheng; R Harvey; P C Espino; K Semba; T Yamamoto; K Toyoshima; A E Smith
Journal:  EMBO J       Date:  1988-12-01       Impact factor: 11.598

9.  Activation of the pp60c-src kinase by middle T antigen binding or by dephosphorylation.

Authors:  S A Courtneidge
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

10.  The complex of polyoma virus middle-T antigen and pp60c-src.

Authors:  S A Courtneidge; A E Smith
Journal:  EMBO J       Date:  1984-03       Impact factor: 11.598

View more
  34 in total

Review 1.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

2.  Characterization of the interaction of polyomavirus middle T antigen with type 2A protein phosphatase.

Authors:  E T Ulug; A J Cartwright; S A Courtneidge
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

3.  An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases.

Authors:  A L Burkhardt; J B Bolen; E Kieff; R Longnecker
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  Interactions of polyomavirus middle T with the SH2 domains of the pp85 subunit of phosphatidylinositol-3-kinase.

Authors:  M Yoakim; W Hou; Y Liu; C L Carpenter; R Kapeller; B S Schaffhausen
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

5.  Stoichiometry of cellular and viral components in the polyomavirus middle-T antigen-tyrosine kinase complex.

Authors:  S H Cheng; P C Espino; J Marshall; R Harvey; A E Smith
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

Review 6.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

7.  Mutation of a cysteine residue in polyomavirus middle T antigen abolishes interactions with protein phosphatase 2A, pp60c-src, and phosphatidylinositol-3 kinase, activation of c-fos expression, and cellular transformation.

Authors:  G M Glenn; W Eckhart
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Endothelin-1 induces tyrosine phosphorylation in human blood monocytes.

Authors:  L J Chisholm; D K Agrawal; T J Pearson; J D Edwards
Journal:  Mol Cell Biochem       Date:  1996-06-07       Impact factor: 3.396

9.  Novel monoclonal antibodies that differentiate between the binding of pp60c-src or protein phosphatase 2A by polyomavirus middle T antigen.

Authors:  S M Dilworth; V P Horner
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.

Authors:  Cecile Rouleau; Arun T Pores Fernando; Justin H Hwang; Nathalie Faure; Tao Jiang; Elizabeth A White; Thomas M Roberts; Brian S Schaffhausen
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.